Yarrow Bioscience完成与VYNE合并,Graves病药物YB-101启动II期临床

环球市场播报
Jul 27

  临床阶段生物技术公司Yarrow Bioscience今日宣布,已完成与VYNE Therapeutics的合并,并同步完成约2亿美元私募融资。合并后公司将继续以Yarrow Bioscience名义运营,其普通股预计于7月28日在纳斯达克资本市场挂牌交易,股票代码为“YARW”。

  Yarrow的核心管线YB-101是一款潜在同类首创的抗促甲状腺激素受体单克隆抗体,旨在通过阻断TSHR直接干预Graves病和甲状腺眼病的核心致病机制。目前,YB-101已启动针对GD患者的IIa/IIb期临床试验,并获得美国FDA快速通道认定,IIa期数据预计于2027年下半年读出。

  公司总裁兼首席执行官表示,现有GD和TED治疗手段存在局限性,YB-101通过靶向TSHR有望直接阻断疾病进程,为患者带来新的治疗选择。

  本次融资由RTW Investments领投,OrbiMed、Janus Henderson Investors等机构参与,所筹资金预计可支撑公司运营至2028年。Yarrow计划在获得IIa期数据后,于2028年上半年启动约200例患者的IIb剂量探索阶段。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:张俊 SF065

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10